Drug Profile
Lerociclib - G1 Therapeutics
Alternative Names: EQ-132; G1T-38; GB-491Latest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator G1 Therapeutics
- Developer EQRx; G1 Therapeutics; Genor Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration HER2 negative breast cancer
- Phase I/II Non-small cell lung cancer
- No development reported Cancer
Most Recent Events
- 19 Mar 2024 Preregistration for HER2-negative-breast-cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (PO)
- 31 Dec 2023 G1 Therapeutics has patents pending for Lerociclib in multiple countries in the World
- 31 Dec 2023 G1 Therapeutics has patents protection for Lerociclib in multiple countries in the World